Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution

American Journal of Cardiology

Volumn 110, Issue 1, 2012, Pages 67-71

  Sánchez Quesada, José L ^a   Vinagre, Irene ^a   De Juan Franco, Elena ^a   Sánchez Hernández, Juan ^b   Blanco Vaca, Francisco ^a,b,c   Ordóñez Llanos, Jordi ^a,c   Pérez, Antonio ^a,b  

^a Biomedical Research Institute IIB   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN B; EZETIMIBE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; ENZYME ACTIVITY; ENZYME LOCALIZATION; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; LIFESTYLE MODIFICATION; LIPID ANALYSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CHROMATOGRAPHY, ION EXCHANGE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GLYCEMIC INDEX; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 84862299070     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.02.051     Document Type: Article

References (22)

1. E. Eschwege The dysmetabolic syndrome, insulin resistance and increased cardiovascular (CV) morbidity and mortality in type 2 diabetes: aetiological factors in the development of CV complications Diabetes Metab 29 2003 6S19-6S27
2. P.G. Scheffer, G. Bos, H.G. Volwater, J.M. Dekker, R.J. Heine, T. Teerlink Associations of LDL size with in vitro oxidizability and plasma levels of in vivo oxidized LDL in type 2 diabetic patients Diabet Med 20 2003 563 567
3. A.M. Wagner, J. Ordonez-Llanos, O. Jorba, A. Perez Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes Metabolism 53 2004 1516
4. J.L. Sánchez-Quesada, A. Perez, A. Caixas, M. Rigla, A. Payes, S. Benitez, J. Ordonez-Llanos Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative modification J Clin Endocrinol Metab 86 2001 3243 3249
5. S. Tsimikas, L.D. Tsironis, A.D. Tselepis New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease Arterioscler Thromb Vasc Biol 27 2007 2094 2099
6. A. Thompson, P. Gao, L. Orfei, S. Watson, E. Di Angelantonio, S. Kaptoge, C. Ballantyne, C.P. Cannon, M. Criqui, M. Cushman, A. Hofman, C. Packard, S.G. Thompson, R. Collins, J. Danesh Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies Lancet 375 2010 1536 1544
7. C.C. Tellis, A.D. Tselepis The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma Biochim Biophys Acta 1791 2009 327 338
8. T. Kujiraoka, T. Iwasaki, M. Ishihara, M. Ito, M. Nagano, A. Kawaguchi, S. Takahashi, J. Ishi, M. Tsuji, T. Egashira, I.P. Stepanova, N.E. Miller, H. Hattori Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus J Lipid Res 44 2003 2006 2014
9. I. Gazi, E.S. Lourida, T. Filippatos, V. Tsimihodimos, M. Elisaf, A.D. Tselepis Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma Clin Chem 51 2005 2264 2273
10. S. Benitez, J.L. Sánchez-Quesada, V. Ribas, O. Jorba, F. Blanco-Vaca, F. Gonzalez-Sastre, J. Ordonez-Llanos Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction Circulation 108 2003 92 96
11. V.G. Saougos, A.P. Tambaki, M. Kalogirou, M. Kostapanos, I.F. Gazi, R.L. Wolfert, M. Elisaf, A.D. Tselepis Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2 Arterioscler Thromb Vasc Biol 27 2007 2236 2243
12. A.M. Wagner, J. Ordonez-Llanos, A. Caixas, R. Bonet, A. de Leiva, A. Perez Quantitative effect of glycaemic improvement on the components of diabetic dyslipidaemia: a longitudinal study Diabetes Res Clin Pract 68 2005 81 83
13. J.L. Sánchez-Quesada, S. Benitez, C. Otal, M. Franco, F. Blanco-Vaca, J. Ordonez-Llanos Density distribution of electronegative LDL in normolipemic and hyperlipemic subjects J Lipid Res 43 2002 699 705
14. J.L. Sánchez-Quesada, R. Homs-Serradesanferm, J. Serrat-Serrat, J.R. Serra-Grima, F. Gonzalez-Sastre, J. Ordonez-Llanos Increase of LDL susceptibility to oxidation occurring after intense, long duration aerobic exercise Atherosclerosis 118 1995 297 305
15. E. de Juan-Franco, A. Pérez, V. Ribas, J.A. Sanchez- Hernandez, F. Blanco-Vaca, J. Ordonez-Llanos, J.L. Sánchez-Quesada Standarization of a method to evaluate the antioxidant capacity of high-density lipoproteins Int J Biomed Sci 5 2009 402 410
16. J.L. Sánchez-Quesada, A. Perez, A. Caixas, J. Ordonmez-Llanos, G. Carreras, A. Payes, F. Gonzalez-Sastre, A. de Leiva Electronegative low density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycaemic control Diabetologia 39 1996 1469 1476
17. C. Bancells, S. Benitez, J. Ordonez-Llanos, K. Oorni, P.T. Kovanen, R.W. Milne, J.L. Sánchez-Quesada Immunochemical analysis of the electronegative LDL subfraction shows that abnormal N-terminal apolipoprotein B conformation is involved in increased binding to proteoglycans J Biol Chem 286 2011 1125 1133
18. S. Lund-Katz, P.M. Laplaud, M.C. Phillips, M.J. Chapman Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction Biochemistry 37 1998 12867 12874
19. J.W. Gaubatz, B.K. Gillard, J.B. Massey, R.C. Hoogeveen, M. Huang, E.E. Lloyd, J.L. Raya, C.Y. Yang, H.J. Pownall Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2) J Lipid Res 48 2007 348 357
20. T.A. Musliner, R.M. Krauss Lipoprotein subspecies and risk of coronary disease Clin Chem 34 1988 B78 B83
21. A.I. Papathanasiou, E.S. Lourida, L.D. Tsironis, J.A. Goudevenos, A.D. Tselepis Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment Atherosclerosis 196 2008 289 297
22. V. Tsimihodimos, S.A. Karabina, A.P. Tambaki, E. Bairaktari, J.A. Goudevenos, M.J. Chapman, M. Elisaf, A.D. Tselepis Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB Arterioscler Thromb Vasc Biol 22 2002 306 311